Role of matrix-degrading enzymes in melanoma progression;Bedeutung von matrix-degradierenden enzymen für die melanomprogression

Hautarzt

Volumn 53, Issue 9, 2002, Pages 587-595

  Hofmann, U B ^a   Becker, J C ^a   Brocker E B ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Adhesion molecules; Extracellular matrix; Matrix metalloproteinases; Melanoma; Proteases; Tumor progression

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANGIOGENESIS INHIBITOR; APROTININ; ASPARTIC PROTEINASE; BATIMASTAT; CATHEPSIN B; CATHEPSIN D; CATHEPSIN H; CATHEPSIN L; CELL ADHESION MOLECULE; COLLAGENASE 3; CYSTATIN; CYSTEINE PROTEINASE; CYSTEINE PROTEINASE INHIBITOR; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MARIMASTAT; MATRIX METALLOPROTEINASE; PEPSTATIN; PLASMIN; PROTEINASE INHIBITOR; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ANGIOGENESIS; CELL ADHESION; ENZYME INHIBITION; EXTRACELLULAR MATRIX; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MELANOMA; MELANOMA CELL; NONHUMAN; PROTEINASE INHIBITION; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS;

EID: 0036933579     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-001-0301-0     Document Type: Review

References (67)

1. Airola K, Karonen T, Vaalamo M et al. (1999) Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas. Br J Cancer 80:733-743
2. Albelda SM, Mette SA, Elder DE et al. (1990) Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 50:6757-6764
3. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1-22
4. 3,8-10 is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells. J Cell Physiol 176:206-215
5. Brenneisen P, Wenk J, Klotz LO et al. (1998) Central role of Ferrous/Ferric iron in the ultraviolet B irradiation-mediated signaling pathway leading to increased interstitial collagenase (matrix-degrading metalloprotease (MMP)-1) and stromelysin-1 (MMP-3) mRNA levels in cultured human dermal fibroblasts. J Biol Chem 273:5279-5287
6. Brooks PC, Strömblad S, Sanders LC et al. (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3. Cell 85:683-693
7. Butler GS, Butler MJ, Atkinson SJ et al. (1998) The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem 273:871-880
8. Curran S, Murray GI (2000) Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 36:1621-1630
9. d'Ortho MP, Will H, Atkinson S et al. (1997) Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases. Eur J Biochem 250:751-757
10. Danen EH, ten Berge PJ, van Muijen GNP et al. (1994) Emergence of alpha 5 beta 1 fibronectin-and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology 24:249-256
11. de Vries TJ, Quax PH, Denijn M et al. (1994) Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. Am J Pathol 144:70-81
12. de Vries TJ, van Muijen GNP, Ruiter DJ (1996) The plasminogen activation system in melanoma cell lines and in melanocytic lesions. Melanoma Res 6:79-88
13. Delbaldo C, Masouye I, Saurat JH, Vasalli JD, Sappino AP (1994) Plasminogen activation in melanocytic neoplasia. Cancer Res 54:4547-4552
14. Deryugina EI, Bourdon MA, Jungwirth K, Smith JW, Strongin AY (2000) Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase. Int J Cancer 86:15-23
15. Deryugina EI, Ratnikov B, Monosov E et al. (2001) MT1-MMP initiates activation of proMMP-2 and integrin αvβ3 promotes maturation of MMP-2 in breast carcino cells. Exp Cell Res 263:209-223
16. Duffy MJ (1996) Proteases as prognostic markers in cancer. Clin Cancer Res 2:613-618
17. Durko M, Navab R, Shibata HR, Brodt P (1997) Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta 1356:271-280
18. Eckes B, Zigrino P, Kessler D et al. (2000) Fibroblast-matrix interactions in wound healing and fibrosis. Matrix Biol 19:325-332
19. Ferrier CM, Van-Muijen GN, Ruiter DJ (1998) Proteases in cutaneous melanoma. Ann Med 30:431-442
20. Filardo EJ, Brooks PC, Deming SL et al. (1995) Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. J Cell Biol 130:441-450
21. Fisher GJ, Talwar HS, Lin J et al. (1998) Retinoic acid inhibits induction of c-Jun protein by ultraviolet radiation that occurs subsequent to activation of mitogen-activated protein kinase pathways in human skin in vivo. J Clin Invest 101:1432-1440
22. Fräki JE, Nieminen S, Hopsu H (1979) Proteolytic enzymes and plasminogen activator in melanoma. J Cutan Pathol 6:195-200
23. Friedl P, Bröcker EB, Zanker KS (1998) Integrins, cell matrix interactions and cell migration strategies: fundamental differences in leukocytes and tumor cells. Cell Adhes Commun 6:225-236
24. Fröhlich E, Schaumburg LG, Klessen C (1995) Immunocytochemical and immunoelectron microscopic demonstration of cathepsin B in human malignant melanoma. Br J Dermatol 132:867-875
25. Goldmann T, Suter L, Ribbert D, Otto F (1999) The expression of proteolytic enzymes at the dermal invading front of primary cutaneous melanoma predicts metastasis. Pathol Res Pract 195:171-175
26. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol 74:111-122
27. Herouy Y, Vanscheidt W, Schopf E, Norgauer J (1999) Gen- und Proteinfamilie der Matrix-Metalloproteinasen: Struktur, Funktion und Expression in der Haut. Hautarzt 50:825-836
28. 3 correlates with activation of membrane-type matrix metalloproteinase-1 (MT1-MMP) and matrix metalloproteinase-2 (MMP-2) in human melanoma cells invitro and in vivo. Int J Cancer 87:12-19
29. Hofmann UB, Westphal JR, van Muijen GNP, Ruiter DJ (2000) Matrix metalloproteinases in human melanoma. Review article. J Invest Dermatol 337-344
30. 3 and matrix metalloproteinase-2 (MMP-2) coincides with MMP-2 activation: correlation with melanoma progression. J Invest Dermatol 115:625-632
31. Hofmann UB, Westphal JR, Waas ET, Zendman AJW, Cornelissen IMHA, Ruiter DJ, van Muijen GNP (1999) Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression. Br J Cancer 81:774-782
32. Hofmann UB, Westphal JR, Zendman AJ et al. (2000) Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type matrix metalloproteinase 1 (MT1-MMP) correlate with melanoma progression. J Pathol 191:245-256
33. Hsu MY, Shih DT, Meier FE et al. (1998) Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma [see comments]. Am J Pathol 153:1435-1442
34. Itoh T, Tanioka M, Matsuda H et al. (1999) Experimental metastasis is suppressed in MMP-9-deficient mice. Clin Exp Metastasis 17:177-181
35. Kageshita T, Yoshii A, Kimura T et al. (1995) Biochemical and immunohistochemical analysis of cathepsins B, H, L and D in human melanocytic tumours. Arch Dermatol Res 287:266-272
36. Klein CE, Steinmayer T, Kaufmann D et al. (1991) Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 96:281-284
37. Kos J, Stabuc B, Schweiger A et al. (1997) Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients. Clin Cancer Res 3:1815-1822
38. Krüger A, Soeltl R, Sopov I et al. (2001) Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res 61:1272-1275
39. Krejci PN (1997) Innovative therapy with metalloprotease inhibitors. Hautarzt 48:81-83
40. Kurschat P, Mauch C (2000) Mechanisms of metastasis. Clin Exp Dermatol 25:482-489
41. Kurschat P, Zigrino P, Nischt R et al. (1999) Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem 274:21056-21062
42. MacDougall JR, Bani MR, Lin Y et al. (1999) "Proteolytic switching": opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression. Br J Cancer 80:504-512
43. Marks R (2000) Epidemiology of melanoma. Clin Exp Dermatol 25:459-463
44. Mazzieri R, Masiero L, Zanetta L et al. (1997) Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16:2319-2332
45. Murphy G, Gavrilovic J (1999) Proteolysis and cell migration: creating a path? Curr Opin Cell Biol 11:614-621
46. Nagase H, Woessner-JF J (1999) Matrix metalloproteinases. J Biol Chem 274:21491-21494
47. Nakahara H, Howard L, Thompson EW et al. (1997) Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci USA 94:7959-7964
48. Natali PG, Nicotra MR, Bartolazzi A et al. (1993) Integrin expression in cutaneous malignant melanoma: association of the alpha 3/beta 1 heterodimer with tumor progression. Int J Cancer 54:68-72
49. Nemeth JA, Rafe A, Steiner M, Goolsby CL (1996) TIMP-2 growth-stimulatory activity: a concentration- and cell type-specific response in the presence of insulin. Exp Cell Res 224:110-115
50. Otto FJ, Goldmann T, Biess B et al. (1999) Prognostic classification of malignant melanomas by combining clinical, histological, and immunohistochemical parameters. Oncology 56:208-214
51. Quax PH, Van-Muijen GN, Weening VE et al. (1991) Metastatic behavior of human melanoma cell lines in nude mice correlates with urokinase-type plasminogen activator, its type-1 inhibitor, and urokinase-mediated matrix degradation. J Cell Biol 115:191-199
52. Rasmussen HS, McCann PP (1997) Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. Pharmacol Ther 75:69-75
53. Ray JM, Stetler-Stevenson WG (1995) Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J 14:908-917
54. Sato H, Takino T, Okada Y et al. (1994) A matrix metalloproteinase expressed on the surface of invasive tumour cells [see comments]. Nature 370:61-65
55. Seftor RE, Seftor EA, Hendrix MJ (1999) Molecular role(s) for integrins in human melanoma invasion. Cancer Metastasis Rev 18:359-375
56. 3 by an organic molecule inhibits angiogenesis and tumor growth in vivo. Proc Natl Acad Sci USA 98:119-124
57. Takahashi K, Eto H, Tanabe KK (1999) Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer 80:387-395
58. Väisänen A, Kallioinen M, Taskinen PJ, Turpeenniemi-Hujanen T (1998) Prognostic value of MMP-2 immunoreactive protein (72kD type IV collagenase) in primary skin melanoma. J Pathol 186:51-58
59. Väisänen A, Tuominen H, Kallioinen M, Turpeenniemi Hujanen T (1996) Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol 180:283-289
60. van den Oord JJ, Paemen L, Opdenakker G, de Wolf Peeters C (1997) Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 151:665-670
61. Wandel E, Grasshoff A, Mittag M et al. (2000) Fibroblasts surrounding melanoma express elevated levels of matrix metalloproteinase-1 (MMP-1) and intercellular adhesion molecule-1 (ICAM-1) in vitro. Exp Dermatol 9:34-41
62. Westermarck J, Kähäri VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781-792
63. Westphal JR, Ruiter DJ, de Waal RM (2000) Anti-angiogenic treatment of human cancer: pitfalls and promises. Int J Cancer 86:870-873
64. Woolley DE, Grafton CA (1980) Collagenase immunolocalization studies of cutaneous secondary melanomas. Br J Cancer 42:260-265
65. Yoshii A, Kageshita T, Tsushima H, Ono T (1995) Clinical relevance of cathepsin B-like enzyme activity and cysteine proteinase inhibitor in melanocytic tumours. Arch Dermatol Res 287:209-213
66. Yu Q, Stamenkovic I (1999) Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13:35-48
67. Zucker S, Drews M, Conner C et al.(1998) Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1 - matrix metalloproteinase 1 (MT1-MMP). J Biol Chem 273:1216-1222